Drug Profile


Alternative Names: MDL 11939; MDL 11939A

Latest Information Update: 04 Apr 1995

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aventis
  • Class Antiglaucomas; Anxiolytics; Small molecules
  • Mechanism of Action Potassium channel antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Arrhythmias

Most Recent Events

  • 04 Apr 1995 A study in patients with generalised anxiety disorder has been added to the therapeutic trials and adverse events sections
  • 10 Mar 1995 Discontinued-III for Anxiety disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top